Dendritic Cells and Cancer Immunity

Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012

Mildner, 2014, Development and function of dendritic cell subsets, Immunity, 40, 642, 10.1016/j.immuni.2014.04.016

Merad, 2013, The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting, Annu. Rev. Immunol., 31, 563, 10.1146/annurev-immunol-020711-074950

Guilliams, 2016, Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species, Immunity, 45, 669, 10.1016/j.immuni.2016.08.015

Hildner, 2008, Batf3 deficiency reveals a critical role for CD8a+ dendritic cells in cytotoxic T cell immunity, Science, 322, 1097, 10.1126/science.1164206

Fuertes, 2011, Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells, J. Exp. Med., 208, 2005, 10.1084/jem.20101159

Salmon, 2016, Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition, Immunity, 44, 924, 10.1016/j.immuni.2016.03.012

Sanchez-Paulete, 2015, Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells, Cancer Discov., 6, 71, 10.1158/2159-8290.CD-15-0510

Segura, 2015, Cross-presentation in mouse and human dendritic cells, Adv. Immunol., 127, 1, 10.1016/bs.ai.2015.03.002

Desch, 2011, CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen, J. Exp. Med., 208, 1789, 10.1084/jem.20110538

Headley, 2016, Visualization of immediate immune responses to pioneer metastatic cells in the lung, Nature, 531, 513, 10.1038/nature16985

Roberts, 2016, Critical role for CD103+/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma, Cancer Cell, 30, 324, 10.1016/j.ccell.2016.06.003

Engelhardt, 2012, Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells, Cancer Cell, 21, 402, 10.1016/j.ccr.2012.01.008

Anderson, 2007, Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer, J. Immunol., 178, 1268, 10.4049/jimmunol.178.3.1268

Gerner, 2008, Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses, J. Immunol., 181, 155, 10.4049/jimmunol.181.1.155

Zhu, 2015, CD4+ T cell help selectively enhances high-avidity tumor antigen-specific CD8+ T cells, J. Immunol., 195, 3482, 10.4049/jimmunol.1401571

Bos, 2010, CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes, Cancer Res., 70, 8368, 10.1158/0008-5472.CAN-10-1322

Schietinger, 2010, Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase, J. Exp. Med., 207, 2469, 10.1084/jem.20092450

Tomita, 2013, Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor, Clin. Cancer Res., 19, 4508, 10.1158/1078-0432.CCR-13-0197

Marzo, 2000, Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity, J. Immunol., 165, 6047, 10.4049/jimmunol.165.11.6047

Broz, 2014, Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity, Cancer Cell, 26, 638, 10.1016/j.ccell.2014.09.007

den Haan, 2002, Constitutive versus activation-dependent cross-presentation of immune complexes by CD8+ and CD8– dendritic cells in vivo, J. Exp. Med., 196, 817, 10.1084/jem.20020295

Platzer, 2015, IgE/FcɛRI-mediated antigen cross-presentation by dendritic cells enhances anti-tumor immune responses, Cell Rep., 10, 1487, 10.1016/j.celrep.2015.02.015

Desch, 2014, Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction, Nat. Commun., 5, 4674, 10.1038/ncomms5674

Ma, 2013, Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells, Immunity, 38, 729, 10.1016/j.immuni.2013.03.003

Jakubzick, 2008, Optimization of methods to study pulmonary dendritic cell migration reveals distinct capacities of DC subsets to acquire soluble versus particulate antigen, J. Immunol. Methods, 337, 121, 10.1016/j.jim.2008.07.005

Zong, 2016, Tumor-derived factors modulating dendritic cell function, Cancer Immunol. Immunother., 65, 821, 10.1007/s00262-016-1820-y

Ruffell, 2014, Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells, Cancer Cell, 26, 623, 10.1016/j.ccell.2014.09.006

Spranger, 2015, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity, Nature, 523, 231, 10.1038/nature14404

Mellman, 2001, Dendritic cells: specialized and regulated antigen processing machines, Cell, 106, 255, 10.1016/S0092-8674(01)00449-4

Zelenay, 2013, Adaptive immunity after cell death, Trends Immunol., 34, 329, 10.1016/j.it.2013.03.005

Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu. Rev. Immunol., 31, 51, 10.1146/annurev-immunol-032712-100008

Müller, 2010, The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation, Allergy, 65, 1545, 10.1111/j.1398-9995.2010.02426.x

Ghiringhelli, 2009, Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors, Nat. Med., 15, 1170, 10.1038/nm.2028

Idzko, 2007, Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells, Nat. Med., 13, 913, 10.1038/nm1617

Obeid, 2007, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat. Med., 13, 54, 10.1038/nm1523

Obeid, 2007, Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis, Cell Death Differ., 14, 1848, 10.1038/sj.cdd.4402201

Apetoh, 2007, Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nat. Med., 13, 1050, 10.1038/nm1622

Messmer, 2004, High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization, J. Immunol., 173, 307, 10.4049/jimmunol.173.1.307

Schiraldi, 2012, HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4, J. Exp. Med., 209, 551, 10.1084/jem.20111739

Pfirschke, 2016, Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy, Immunity, 44, 343, 10.1016/j.immuni.2015.11.024

Chiba, 2012, Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1, Nat. Immunol., 13, 832, 10.1038/ni.2376

Woo, 2014, STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors, Immunity, 41, 830, 10.1016/j.immuni.2014.10.017

Deng, 2014, STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors, Immunity, 41, 843, 10.1016/j.immuni.2014.10.019

Fuertes, 2013, Type I interferon response and innate immune sensing of cancer, Trends Immunol., 34, 67, 10.1016/j.it.2012.10.004

Diamond, 2011, Type I interferon is selectively required by dendritic cells for immune rejection of tumors, J. Exp. Med., 208, 1989, 10.1084/jem.20101158

Corrales, 2016, The host STING pathway at the interface of cancer and immunity, J. Clin. Invest., 126, 2404, 10.1172/JCI86892

Pasparakis, 2015, Necroptosis and its role in inflammation, Nature, 517, 311, 10.1038/nature14191

Yatim, 2015, RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8+ T cells, Science, 350, 328, 10.1126/science.aad0395

Aaes, 2016, Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity, Cell Rep., 15, 274, 10.1016/j.celrep.2016.03.037

Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348

Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095

Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596

DuPage, 2012, Expression of tumour-specific antigens underlies cancer immunoediting, Nature, 482, 405, 10.1038/nature10803

Scarlett, 2012, Ovarian cancer progression is controlled by phenotypic changes in dendritic cells, J. Exp. Med., 209, 495, 10.1084/jem.20111413

Roland, 2009, Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer, PLoS One, 4, e7669, 10.1371/journal.pone.0007669

Tang, 2015, Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling, Cell Rep., 13, 2851, 10.1016/j.celrep.2015.11.053

Doedens, 2010, Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression, Cancer Res., 70, 7465, 10.1158/0008-5472.CAN-10-1439

Colegio, 2014, Functional polarization of tumour-associated macrophages by tumour-derived lactic acid, Nature, 513, 559, 10.1038/nature13490

Liang, 2015, A2B adenosine receptor activation switches differentiation of bone marrow cells to a CD11c+ Gr-1+ dendritic cell subset that promotes the Th17 response, Immun. Inflamm. Dis., 3, 360, 10.1002/iid3.74

Gottfried, 2006, Tumor-derived lactic acid modulates dendritic cell activation and antigen expression, Blood, 107, 2013, 10.1182/blood-2005-05-1795

O’Neill, 2016, Immunometabolism governs dendritic cell and macrophage function, J. Exp. Med., 213, 15, 10.1084/jem.20151570

Cubillos-Ruiz, 2015, ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis, Cell, 161, 1527, 10.1016/j.cell.2015.05.025

Natsuaki, 2014, Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin, Nat. Immunol., 15, 1064, 10.1038/ni.2992

Iijima, 2014, T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells, Science, 346, 93, 10.1126/science.1257530

Pitzalis, 2014, Ectopic lymphoid-like structures in infection, cancer and autoimmunity, Nat. Rev. Immunol., 14, 447, 10.1038/nri3700

Dieu-Nosjean, 2016, Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers, Immunol. Rev., 271, 260, 10.1111/imr.12405

Thompson, 2010, Tumor masses support naive T cell infiltration, activation, and differentiation into effectors, J. Exp. Med., 207, 1791, 10.1084/jem.20092454

Joshi, 2015, Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses, Immunity, 43, 579, 10.1016/j.immuni.2015.08.006

Schrama, 2008, Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue, Cancer Immunol. Immunother., 57, 85, 10.1007/s00262-007-0352-x

Yu, 2004, Priming of naive T cells inside tumors leads to eradication of established tumors, Nat. Immunol., 5, 141, 10.1038/ni1029

Kirk, 2001, The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally, Cancer Res., 61, 8794

Palucka, 2013, Dendritic-cell-based therapeutic cancer vaccines, Immunity, 39, 38, 10.1016/j.immuni.2013.07.004

Fu, 2015, STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade, Sci. Transl. Med., 7, 283ra52, 10.1126/scitranslmed.aaa4306

Russell, 2012, Oncolytic virotherapy, Nat Biotechnol., 30, 658, 10.1038/nbt.2287

Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N. Engl. J. Med., 363, 411, 10.1056/NEJMoa1001294

Burch, 2000, Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer, Clin. Cancer Res., 6, 2175

Carreno, 2013, IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity, J. Clin. Invest., 123, 3383, 10.1172/JCI68395

Carreno, 2015, A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells, Science, 348, 803, 10.1126/science.aaa3828

Kleindienst, 2003, Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo, J. Immunol., 170, 2817, 10.4049/jimmunol.170.6.2817

Yewdall, 2010, CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells, PLoS One, 5, e11144, 10.1371/journal.pone.0011144

Petersen, 2011, Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines, PLoS One, 6, e17657, 10.1371/journal.pone.0017657

Mitchell, 2015, Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients, Nature, 519, 366, 10.1038/nature14320

Le, 2015, Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer, J. Clin. Oncol., 33, 1325, 10.1200/JCO.2014.57.4244

Kranz, 2016, Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy, Nature, 534, 396, 10.1038/nature18300

Kawarada, 2001, NK- and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides, J. Immunol., 167, 5247, 10.4049/jimmunol.167.9.5247

Heckelsmiller, 2002, Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model, J. Immunol., 169, 3892, 10.4049/jimmunol.169.7.3892

Ohkuri, 2014, STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment, Cancer Immunol. Res., 2, 1199, 10.1158/2326-6066.CIR-14-0099

Vicari, 2002, Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody, J. Exp. Med., 196, 541, 10.1084/jem.20020732

Swiecki, 2015, The multifaceted biology of plasmacytoid dendritic cells, Nat. Rev. Immunol., 15, 471, 10.1038/nri3865

Villadangos, 2008, Antigen-presentation properties of plasmacytoid dendritic cells, Immunity, 29, 352, 10.1016/j.immuni.2008.09.002

Conrad, 2012, Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells, Cancer Res., 72, 5240, 10.1158/0008-5472.CAN-12-2271

Treilleux, 2004, Dendritic cell infiltration and prognosis of early stage breast cancer, Clin. Cancer Res., 10, 7466, 10.1158/1078-0432.CCR-04-0684

Le Mercier, 2013, Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment, Cancer Res., 73, 4629, 10.1158/0008-5472.CAN-12-3058

Leon, 2008, Monocyte-derived dendritic cells in innate and adaptive immunity, Immunol. Cell Biol., 86, 320, 10.1038/icb.2008.14

Domínguez, 2010, Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation, Immunol. Rev., 234, 90, 10.1111/j.0105-2896.2009.00876.x

Tamoutounour, 2013, Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin, Immunity, 39, 925, 10.1016/j.immuni.2013.10.004

Plantinga, 2013, Conventional and monocyte-derived CD11b+ dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen, Immunity, 38, 322, 10.1016/j.immuni.2012.10.016

Jakubzick, 2013, Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes, Immunity, 39, 599, 10.1016/j.immuni.2013.08.007

Marigo, 2016, T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells, Cancer Cell, 30, 377, 10.1016/j.ccell.2016.08.004